Legacy Advisors LLC Acquires 59 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Legacy Advisors LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,747 shares of the company’s stock after acquiring an additional 59 shares during the quarter. Legacy Advisors LLC’s holdings in Medpace were worth $1,955,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Medpace by 5.9% in the fourth quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock valued at $783,626,000 after acquiring an additional 142,591 shares during the period. TD Asset Management Inc increased its holdings in Medpace by 22.9% during the 1st quarter. TD Asset Management Inc now owns 574,149 shares of the company’s stock valued at $232,042,000 after purchasing an additional 107,108 shares during the period. Epoch Investment Partners Inc. raised its position in Medpace by 15.3% during the 1st quarter. Epoch Investment Partners Inc. now owns 406,446 shares of the company’s stock valued at $164,265,000 after purchasing an additional 53,983 shares during the last quarter. Bessemer Group Inc. lifted its holdings in Medpace by 1.6% in the 1st quarter. Bessemer Group Inc. now owns 394,834 shares of the company’s stock worth $159,572,000 after buying an additional 6,137 shares during the period. Finally, Westwind Capital grew its position in shares of Medpace by 800.1% in the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock worth $156,886,000 after buying an additional 338,610 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on MEDP. Truist Financial started coverage on Medpace in a report on Thursday, August 1st. They set a “hold” rating and a $415.00 target price for the company. Mizuho started coverage on shares of Medpace in a research report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price for the company. William Blair reiterated an “outperform” rating on shares of Medpace in a report on Tuesday, July 23rd. Deutsche Bank Aktiengesellschaft lowered their target price on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research note on Wednesday, July 24th. Finally, Robert W. Baird decreased their price objective on Medpace from $469.00 to $430.00 and set an “outperform” rating for the company in a report on Wednesday, July 24th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $423.00.

Medpace Trading Down 2.9 %

Shares of NASDAQ:MEDP opened at $355.27 on Friday. Medpace Holdings, Inc. has a 12-month low of $227.21 and a 12-month high of $459.77. The stock has a market capitalization of $11.01 billion, a price-to-earnings ratio of 36.22, a PEG ratio of 1.85 and a beta of 1.36. The stock has a fifty day simple moving average of $397.14 and a two-hundred day simple moving average of $396.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The firm had revenue of $528.10 million during the quarter, compared to analyst estimates of $528.41 million. During the same quarter in the previous year, the firm earned $1.93 EPS. Medpace’s quarterly revenue was up 14.6% compared to the same quarter last year. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 11.66 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.